Holen Sie sich die Stockscreener-App
40.07
0.40%
-0.16
Vorhandelsmarkt:
40.21
0.14
+0.35%
Schlusskurs vom Vortag:
$40.23
Offen:
$40.17
24-Stunden-Volumen:
2.10M
Relative Volume:
0.61
Marktkapitalisierung:
$96.01B
Einnahmen:
$49.41B
Nettoeinkommen (Verlust:
$5.59B
KGV:
16.78
EPS:
2.3875
Netto-Cashflow:
$8.32B
1W Leistung:
+1.42%
1M Leistung:
-6.31%
6M Leistung:
-14.31%
1J Leistung:
-16.68%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$39.23
$40.30
52-Wochen-Spanne:
$39.18
$52.68
Sanofi Adr Stock (SNY) Company Profile
Compare SNY vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
40.07 | 96.01B | 49.41B | 5.59B | 8.32B | 2.3875 |
LLY
Lilly Eli Co
|
1,179.27 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
261.44 | 630.04B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
276.47 | 488.55B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
145.60 | 359.22B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
143.75 | 273.23B | 54.66B | 13.58B | 16.05B | 7.0171 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-09 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2026-05-01 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2026-04-20 | Herabstufung | BNP Paribas Exane | Outperform → Neutral |
| 2026-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2026-01-27 | Eingeleitet | Citigroup | Neutral |
| 2026-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2026-01-06 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-12-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-12-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-09-08 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-09-02 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-08-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-03-21 | Eingeleitet | Goldman | Neutral |
| 2025-01-30 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-07-26 | Bestätigt | Argus | Buy |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Fortgesetzt | UBS | Buy |
| 2023-12-05 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-10-30 | Herabstufung | Stifel | Buy → Hold |
| 2023-09-06 | Hochstufung | Berenberg | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-28 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-03-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-12-13 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-08-12 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-08-09 | Herabstufung | UBS | Buy → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-27 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Sell |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-03-17 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-03-11 | Hochstufung | Goldman | Neutral → Buy |
| 2020-02-11 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-01-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-09-20 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-03 | Eingeleitet | Bernstein | Outperform |
| 2019-08-14 | Hochstufung | UBS | Neutral → Buy |
| 2018-12-11 | Hochstufung | Jefferies | Hold → Buy |
| 2018-11-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-10-09 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-10 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2018-08-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-03-23 | Hochstufung | Liberum | Hold → Buy |
| 2018-01-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2017-12-06 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2017-12-01 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2017-11-15 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2017-08-30 | Hochstufung | HSBC Securities | Reduce → Hold |
Alle ansehen
Sanofi Adr Aktie (SNY) Neueste Nachrichten
Retension Pharmaceuticals Announces Pricing of Initial Public Offering - GlobeNewswire Inc.
Press Release : Availability of the aide-mémoire for Q3 2026 results - GlobeNewswire Inc.
Communiqué de presse : Mise en ligne du document «Q3 2026 aide-mémoire » - GlobeNewswire Inc.
Sanofi, Regeneron Expand Immunology Alliance With New Antibodies - Zacks Investment Research
GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential? - Zacks Investment Research
Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59%SNS Insider - GlobeNewswire Inc.
Full issuance would represent about 66.67% of Scinai (SCNI)'s depositary shares under its funding deal. - Stock Titan
Sanofi (SNY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is Regeneron Stock a Bargain Below $800? - The Motley Fool
Recludix Pharma to Present at the Oppenheimer Private Life Sciences Company Showcase - GlobeNewswire Inc.
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff - Zacks Investment Research
Sanofi partners with USA Pickleball to launch "Serve Up Protection" campaign to help protect older adults from COVID-19 with NUVAXOVID - Finviz
RBC Capital initiates Sanofi stock at Sector Perform on transition risks - Investing.com Canada
Monoclonal Antibodies Market to Grow at 11.01% CAGR, Reaching USD 791.28 Billion by 2035 – SNS Insider - GlobeNewswire Inc.
Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight - GlobeNewswire Inc.
Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider - GlobeNewswire Inc.
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70%SNS Insider - GlobeNewswire Inc.
Sanofi ADSADR Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Sanofi ADSADR Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
European ADRs Slipped In US Trading Late Thursday Morning - Finimize
Sanofi-ADR (NASDAQ:SNY): A Dividend Quality Candidate with Solid Profitability - ChartMill
Sanofi stock holds firm as workforce shake-up follows strong Q2 2026 - ad-hoc-news.de
Sanofi stock steadies after strong Q2 2026 and upgraded guidance - Ad-hoc-news.de
Sanofi stock steadies as upgraded 2026 guidance follows strong Q2 momentum - AD HOC NEWS
Sanofi stock climbs as MenQuadfi approval and cuts reshape the story - Ad-hoc-news.de
Sanofi stock edges higher as MenQuadfi approval and workforce reshaping define mid-August story - Ad-hoc-news.de
European ADRs Drift Lower In US Trading - Finimize
Sanofi's New Leadership Faces Looming Patent Cliff - Morningstar
6 Undervalued Stocks That Crushed Earnings - morningstar.com
Resilient Sanofi stock edges higher as Q2 2026 growth and R&D reshuffle shape outlook - Ad-hoc-news.de
Sanofi stock holds steady as India unit boosts profit and secures tax refund - Ad-hoc-news.de
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates - Macau Business
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates - GlobeNewswire
Trump considers order on autism and vaccines: which stocks are most exposed? - Investing.com
Nurix earns $10m milestone as Sanofi starts STAT6 degrader trial - Investing.com Nigeria
ETFs Investing in Sanofi SA Sponsored ADR Stocks - tradingview.com
Key facts: Sanofi SA Sponsored ADR files H1 2026; halts three drugs - TradingView
What's behind Sanofi's latest 5.4% stock pullback? - tradersunion.com
European ADRs Jump In US Trading As Banks Lead - Finimize
Sanofi ADR earnings beat by $1.30, revenue topped estimates - investing.com
ETFs Investing in Sanofi SA Sponsored ADR Stocks - TradingView
ETFs Investing in Sanofi SA Sponsored ADR Stocks - TradingView
Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews - GlobeNewswire Inc.
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering - GlobeNewswire Inc.
Antiparasitic Drugs Market Report Released — Examines Antimalarials, Anthelmintics, Antiprotozoals, Ectoparasiticides, and Neglected Tropical Disease Therapies - GlobeNewswire Inc.
Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various Indexes - GlobeNewswire Inc.
Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading Warnings - Sahm
Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider - GlobeNewswire Inc.
Ericsson Stock Slumps As ADR Underperformance Weighs On Traders - StocksToTrade
SANOFI-ADR (NASDAQ:SNY): A Decent Value Stock With Strong Fundamentals and an Undervalued Profile - ChartMill
Finanzdaten der Sanofi Adr-Aktie (SNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.09%
3.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):